Ameritas Investment Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ameritas Investment Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$100K	Hold	7,203	–	–	﹤0.01%	1700
2025 Q4	$87K	Buy	7,203 +1,409	+24%	+$19.1K	﹤0.01%	1780
2025 Q3	$78.7K	Sell	5,794 -1,287	-18%	-$12.1K	﹤0.01%	1841
2025 Q2	$45.4K	Buy	+7,081	New	+$34.4K	﹤0.01%	2244
2024 Q2	–	Sell	-5,046	Closed	-$14.3K	–	3125
2024 Q1	$14.3K	Hold	5,046	–	–	﹤0.01%	2697
2023 Q4	$74.3K	Hold	5,046	–	–	﹤0.01%	1925
2023 Q3	$92.4K	Buy	5,046 +1,011	+25%	+$21.4K	﹤0.01%	1717
2023 Q2	$87K	Hold	4,035	–	–	﹤0.01%	1692
2023 Q1	$118K	Hold	4,035	–	–	﹤0.01%	1436
2022 Q4	$153K	Buy	4,035 +1,271	+46%	+$45.1K	0.01%	1315
2022 Q3	$77K	Buy	2,764 +2,020	+272%	+$50.4K	﹤0.01%	1678
2022 Q2	$14K	Hold	744	–	–	﹤0.01%	2708
2022 Q1	$10K	Buy	+744	New	+$16.8K	﹤0.01%	2788

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Ameritas Investment Partners's AMLX Position: Q1 2026 in Review

Ameritas Investment Partners held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 7,203 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #1700.

Ameritas Investment Partners first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $153K in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Ameritas Investment Partners held 7,203 shares of Amylyx Pharmaceuticals worth $100K as of Q1 2026.
Ameritas Investment Partners left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1700 holding.
Ameritas Investment Partners first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
Ameritas Investment Partners's Amylyx Pharmaceuticals position peaked at $153K in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.